Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Outstanding (Weighted Average) (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Shares Outstanding (Weighted Average) readings, the most recent being $14.1 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 30.82% to $14.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.1 million, a 30.82% increase, with the full-year FY2025 number at $3.6 billion, up 47925.45% from a year prior.
  • Shares Outstanding (Weighted Average) hit $14.1 million in Q1 2026 for Atara Biotherapeutics, down from $3.6 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $3.6 billion in Q4 2025 to a low of $1.4 million in Q3 2023.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $7.5 million (2024), compared with a mean of $234.3 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 97.13% in 2023 and later skyrocketed 47925.45% in 2025.
  • Atara Biotherapeutics' Shares Outstanding (Weighted Average) stood at $102.0 million in 2022, then plummeted by 95.85% to $4.2 million in 2023, then surged by 76.77% to $7.5 million in 2024, then skyrocketed by 47925.45% to $3.6 billion in 2025, then plummeted by 99.61% to $14.1 million in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $14.1 million (Q1 2026), $3.6 billion (Q4 2025), and $13.6 million (Q3 2025) per Business Quant data.